 | Up a level |
Jolidon, Vladimir; Eicher, Manuela; Peytremann-Bridevaux, Isabelle; Aebi, Stefan; Anchisi, Sandro; Bettini, Adrienne; Chalandon, Yves; Dietrich, Pierre-Yves; Duchosal, Michel A; Dürr, Donat; Peters, Solange; von Moos, Roger; Wicki, Andreas; Arditi, Chantal (2024). Identifying the drivers of overall rating of cancer care: Insights from the second wave of the Swiss Cancer Patient Experiences study. (In Press). Cancer Wiley 10.1002/cncr.35506
Mamot, Christoph; Wicki, Andreas; Hasler-Strub, Ursula; Riniker, Salome; Li, Qiyu; Holer, Lisa; Bärtschi, Daniela; Zaman, Khalil; von Moos, Roger; Dedes, Konstantin J; Boos, Laura A; Novak, Urban; Bodmer, Alexandre; Ritschard, Reto; Obermann, Ellen C; Tzankov, Alexandar; Ackermann, Christoph; Membrez-Antonioli, Véronique; Zürrer-Härdi, Ursina; Caspar, Clemens B; ... (2023). A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer. Scientific Reports, 13(1), p. 3705. Nature Publishing Group 10.1038/s41598-023-30950-z
Krebs, Fanny S; Britschgi, Christian; Pradervand, Sylvain; Achermann, Rita; Tsantoulis, Petros; Haefliger, Simon; Wicki, Andreas; Michielin, Olivier; Zoete, Vincent (2022). Structure-based prediction of BRAF mutation classes using machine-learning approaches. Scientific Reports, 12(1), p. 12528. Nature Publishing Group 10.1038/s41598-022-16556-x
Rentsch, Cyrill A; Thalmann, George N; Lucca, Ilaria; Kwiatkowski, Maciej; Wirth, Grégory J; Strebel, Räto T; Engeler, Daniel; Pedrazzini, Augusto; Hüttenbrink, Clemens; Schultze-Seemann, Wolfgang; Torpai, Raimund; Bubendorf, Lukas; Wicki, Andreas; Roth, Beat; Bosshard, Piet; Püschel, Heike; Boll, Daniel T; Hefermehl, Lukas; Roghmann, Florian; Gierth, Michael; ... (2022). A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14. European urology oncology, 5(2), pp. 195-202. Elsevier 10.1016/j.euo.2021.12.006
Irmisch, Anja; Bonilla, Ximena; Chevrier, Stéphane; Lehmann, Kjong-Van; Singer, Franziska; Toussaint, Nora C; Esposito, Cinzia; Mena, Julien; Milani, Emanuela S; Casanova, Ruben; Stekhoven, Daniel J; Wegmann, Rebekka; Jacob, Francis; Sobottka, Bettina; Goetze, Sandra; Kuipers, Jack; Sarabia Del Castillo, Jacobo; Prummer, Michael; Tuncel, Mustafa A; Menzel, Ulrike; ... (2021). The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support. Cancer cell, 39(3), pp. 288-293. Cell Press 10.1016/j.ccell.2021.01.004
Rentsch, Cyrill A; Bosshard, Piet; Mayor, Grégoire; Rieken, Malte; Püschel, Heike; Wirth, Grégory; Cathomas, Richard; Parzmair, Gerald P; Grode, Leander; Eisele, Bernd; Sharma, Hitt; Gupta, Manish; Gairola, Sunil; Shaligram, Umesh; Goldenberger, Daniel; Spertini, François; Audran, Régine; Enoiu, Milica; Berardi, Simona; Hayoz, Stefanie; ... (2020). Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy. Oncoimmunology, 9(1), p. 1748981. Taylor & Francis 10.1080/2162402X.2020.1748981
Kienle, Dirk L.; Dietrich, Daniel; Ribi, Karin; Wicki, Andreas; Quagliata, Luca; Winterhalder, Ralph C.; Koeberle, Dieter; Horber, Daniel; Bastian, Sara; Kueng, Marc; Saletti, Piercarlo; Helbling, Daniel; Baertschi, Daniela; Lugli, Alessandro; Bernhard, Jürg; Andrieu, Christiane; von Moos, Roger (2019). Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. Journal of geriatric oncology, 10(2), pp. 304-310. Elsevier 10.1016/j.jgo.2018.11.011
Wicki, Andreas; Wild, Damian; Prêtre, Vincent; Mansi, Rosalba; Orleth, Annette; Reubi, Jean-Claude; Rochlitz, Christoph; Mamot, Christoph; Mäcke, Helmut R; Christofori, Gerhard (2014). Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors. EJNMMI research, 4(1), p. 9. Springer 10.1186/2191-219X-4-9
Wicki, Andreas; Wild, Damian; Storch, Daniel; Seemayer, Christian; Gotthardt, Martin; Behe, Martin; Kneifel, Stefan; Mihatsch, Michael J; Reubi, Jean-Claude; Mäcke, Helmut R; Christofori, Gerhard (2007). [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clinical cancer research, 13(12), pp. 3696-705. Philadelphia, Pa.: American Association for Cancer Research 10.1158/1078-0432.CCR-06-2965
Wild, Damian; Béhé, Martin; Wicki, Andreas; Storch, Daniel; Waser, Beatrice; Gotthardt, Martin; Keil, Boris; Christofori, Gerhard; Reubi, Jean Claude; Mäcke, Helmut R (2006). [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. Journal of nuclear medicine, 47(12), pp. 2025-33. New York, N.Y.: Society of Nuclear Medicine
